QIAGEN, Lilly to develop Alzheimer’s risk detection test
by
Contributor since / Followers
Contributor since / Followers
3 months ago
jetcityimage/iStock Editorial via Getty Images
- QIAGEN (NYSE:QGEN) has entered into a collaboration with Eli Lilly (NYSE:LLY) for the development of an in vitro diagnostic to help identify patients at risk for developing Alzheimer’s disease.
- The diagnostic panel would be for the detection of APOE genotypes, which can play a role in diagnosing the disease, The product would be integrated with QIAGEN’s QIAstat Dx testing platform, according to a statement.
- QIAGEN (QGEN) said the panel would be able to detect all APOE genotypes, including APOE2, APOE3 and APOE4.
- Lilly (LLY) markets one of the few treatments for Alzheimer’s disease, Kisunla. The product, also known as donanemab, was approved by the FDA in July.
- Biogen (BIIB) and Eisai (OTCPK:ESALF)(OTCPK:ESAIY) also market a treatment for Alzheimer’s. Leqembi, also known as lecanemab, received accelerated approval by the FDA in January 2023 and full approval in July 2024.